These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 22103243)

  • 21. Two small molecule agonists of glucagon-like peptide-1 receptor modulate the receptor activation response differently.
    Cheong YH; Kim MK; Son MH; Kaang BK
    Biochem Biophys Res Commun; 2012 Jan; 417(1):558-63. PubMed ID: 22177947
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A novel thrombin-based triagonist with diabetes-protective and weight-lowering potential.
    Zhang J; Zhang Z; Ma C; Zeng L; Zhang Y; Wang P; Xu L
    Life Sci; 2020 Sep; 256():117853. PubMed ID: 32470452
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Development and characterization of a glucagon-like peptide 1-albumin conjugate: the ability to activate the glucagon-like peptide 1 receptor in vivo.
    Kim JG; Baggio LL; Bridon DP; Castaigne JP; Robitaille MF; Jetté L; Benquet C; Drucker DJ
    Diabetes; 2003 Mar; 52(3):751-9. PubMed ID: 12606517
    [TBL] [Abstract][Full Text] [Related]  

  • 24. New beta-alanine derivatives are orally available glucagon receptor antagonists.
    Lau J; Behrens C; Sidelmann UG; Knudsen LB; Lundt B; Sams C; Ynddal L; Brand CL; Pridal L; Ling A; Kiel D; Plewe M; Shi S; Madsen P
    J Med Chem; 2007 Jan; 50(1):113-28. PubMed ID: 17201415
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Degradation, receptor binding, insulin secreting and antihyperglycaemic actions of palmitate-derivatised native and Ala8-substituted GLP-1 analogues.
    Green BD; Gault VA; Mooney MH; Irwin N; Harriott P; Greer B; Bailey CJ; O'Harte FP; Flatt PR
    Biol Chem; 2004 Feb; 385(2):169-77. PubMed ID: 15101559
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A novel glucagon-like peptide-1/glucagon receptor dual agonist exhibits weight-lowering and diabetes-protective effects.
    Zhou J; Cai X; Huang X; Dai Y; Sun L; Zhang B; Yang B; Lin H; Huang W; Qian H
    Eur J Med Chem; 2017 Sep; 138():1158-1169. PubMed ID: 28772236
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Identification, synthesis, and characterization of new glycogen phosphorylase inhibitors binding to the allosteric AMP site.
    Kristiansen M; Andersen B; Iversen LF; Westergaard N
    J Med Chem; 2004 Jul; 47(14):3537-45. PubMed ID: 15214781
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Molecular modeling of the three-dimensional structure of GLP-1R and its interactions with several agonists.
    Lin F; Wang R
    J Mol Model; 2009 Jan; 15(1):53-65. PubMed ID: 18941807
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Short Hydrophobic Peptides with Cyclic Constraints Are Potent Glucagon-like Peptide-1 Receptor (GLP-1R) Agonists.
    Hoang HN; Song K; Hill TA; Derksen DR; Edmonds DJ; Kok WM; Limberakis C; Liras S; Loria PM; Mascitti V; Mathiowetz AM; Mitchell JM; Piotrowski DW; Price DA; Stanton RV; Suen JY; Withka JM; Griffith DA; Fairlie DP
    J Med Chem; 2015 May; 58(9):4080-5. PubMed ID: 25839426
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Scopariusicides, Novel Unsymmetrical Cyclobutanes: Structural Elucidation and Concise Synthesis by a Combination of Intermolecular [2 + 2] Cycloaddition and C-H Functionalization.
    Zhou M; Li XR; Tang JW; Liu Y; Li XN; Wu B; Qin HB; Du X; Li LM; Wang WG; Pu JX; Sun HD
    Org Lett; 2015 Dec; 17(24):6062-5. PubMed ID: 26617269
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Synthesis, characterization and pharmacodynamics of vitamin-B(12)-conjugated glucagon-like peptide-1.
    Clardy-James S; Chepurny OG; Leech CA; Holz GG; Doyle RP
    ChemMedChem; 2013 Apr; 8(4):582-6. PubMed ID: 23203941
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Discovery of a novel GLP-1/GIP dual receptor agonist CY-5 as long-acting hypoglycemic, anti-obesity agent.
    Liu C; Li C; Cai X; Zou Y; Mo J; Chen B; Cai Y; Han T; Huang W; Qian H; Zhang W
    Bioorg Chem; 2021 Jan; 106():104492. PubMed ID: 33268008
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Design and characterization of novel oxyntomodulin derivatives with potent dual GLP-1/glucagon receptor activation and prolonged antidiabetic effects.
    Pei Z; Zhou D; Yan J; Wang S; Yang X; Pei Z
    Life Sci; 2020 Jul; 253():117651. PubMed ID: 32304764
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Lipidation and conformational constraining for prolonging the effects of peptides: Xenopus glucagon-like peptide 1 analogues with potent and long-acting hypoglycemic activity.
    Han J; Huang Y; Chen X; Zhou F; Fei Y; Fu J
    Eur J Pharm Sci; 2018 Oct; 123():111-123. PubMed ID: 30031858
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Synthesis and in vitro biological evaluation of new pyrimidines as glucagon-like peptide-1 receptor agonists.
    AlNeyadi SS; Adem A; Amer N; Salem AA; Abdou IM
    Bioorg Med Chem Lett; 2017 Nov; 27(22):5071-5075. PubMed ID: 28988756
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Small-molecule agonists for the glucagon-like peptide 1 receptor.
    Knudsen LB; Kiel D; Teng M; Behrens C; Bhumralkar D; Kodra JT; Holst JJ; Jeppesen CB; Johnson MD; de Jong JC; Jorgensen AS; Kercher T; Kostrowicki J; Madsen P; Olesen PH; Petersen JS; Poulsen F; Sidelmann UG; Sturis J; Truesdale L; May J; Lau J
    Proc Natl Acad Sci U S A; 2007 Jan; 104(3):937-42. PubMed ID: 17213325
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Glucagon-like peptide-1 (GLP-1) receptor agonism or DPP-4 inhibition does not accelerate neoplasia in carcinogen treated mice.
    Kissow H; Hartmann B; Holst JJ; Viby NE; Hansen LS; Rosenkilde MM; Hare KJ; Poulsen SS
    Regul Pept; 2012 Nov; 179(1-3):91-100. PubMed ID: 22989472
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Design and preparation of the class B G protein-coupled receptors GLP-1R and GCGR for
    Wang H; Hu W; Liu D; Wüthrich K
    FEBS J; 2021 Jul; 288(13):4053-4063. PubMed ID: 33369025
    [TBL] [Abstract][Full Text] [Related]  

  • 39. High potency antagonists of the pancreatic glucagon-like peptide-1 receptor.
    Montrose-Rafizadeh C; Yang H; Rodgers BD; Beday A; Pritchette LA; Eng J
    J Biol Chem; 1997 Aug; 272(34):21201-6. PubMed ID: 9261127
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Discovery of 5-hydroxyalkyl-4-phenylpyridines as a new class of glucagon receptor antagonists.
    Ladouceur GH; Cook JH; Doherty EM; Schoen WR; MacDougall ML; Livingston JN
    Bioorg Med Chem Lett; 2002 Feb; 12(3):461-4. PubMed ID: 11814820
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.